All Photos(1)

Documents

1356960

USP

Leflunomide

Name: Leflunomide
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₂H₉F₃N₂O₂

CAS Number:

75706-12-6

Molecular Weight:

270.21

MDL number:

MFCD00867593

UNSPSC Code:

41116107

PubChem Substance ID:

329750235

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

leflunomide

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F

InChI

1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)

InChI key

VHOGYURTWQBHIL-UHFFFAOYSA-N

Gene Information

human ... DHODH(1723)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

General description

Leflunomide is a drug with cytotoxic properties. It is generally used as an immunosuppressive agent.

Application

Leflunomide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1357045

1357056

1357067

PHR1568

BP1233

Leflunomide, British Pharmacopoeia (BP) Reference Standard

PHR2878

Pictograms

GHS06

Signal Word

Danger

Hazard Statements

H301,H315,H319,H335

Precautionary Statements

P261 - P264 - P270 - P301 + P310 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.

S Greene et al.

Biochemical pharmacology, 50(6), 861-867 (1995-09-07)

Leflunomide [HWA 486 or RS-34821, 5-methyl-N-(4-trifluoromethylphenyl)-4-isoxazole carboximide] is an immunosuppressive agent effective in the treatment of rheumatoid arthritis. In spite of its clinical potential, its mechanism of action has not been elucidated. Recent studies suggest that leflunomide may interfere with

Leflunomide for chronic sarcoidosis.

Robert P Baughman et al.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 21(1), 43-48 (2004-05-07)

Leflunomide (Arava) is a cytotoxic drug which has been used as a single agent or in combination with methotrexate for the treatment of rheumatoid arthritis. It appears to have less toxicity than methotrexate. The use of leflunomide for sarcoidosis patients

Safety evaluation of leflunomide in rheumatoid arthritis.

Helen I Keen et al.

Expert opinion on drug safety, 12(4), 581-588 (2013-05-15)

Leflunomide is a prodrug which is rapidly converted following oral administration and absorption to an active metabolite with anti-proliferative effects (A77 1726/teriflunomide). Leflunomide was developed as an immunomodulatory agent and subsequently developed as a disease-modifying anti-rheumatic drug (DMARD) for the

Leflunomide therapy for BK virus allograft nephropathy after pediatric kidney transplantation.

Young H Jung et al.

Pediatric transplantation, 17(2), E50-E54 (2012-12-06)

The BK virus (BKV) can be reactivated with immunosuppressive treatment in renal allograft recipients, which can result in interstitial nephritis (BKV-associated nephropathy, BKVAN) and lead to renal allograft failure. Recently, leflunomide has been reported in some case series of BKVAN

Leflunomide in renal transplantation.

W James Chon et al.

Expert review of clinical immunology, 7(3), 273-281 (2011-05-21)

Leflunomide is a synthetic isoxazole-derivative drug that possesses both immunosuppressive and antiviral properties. Although its only US FDA-approved indication is for the treatment of rheumatoid arthritis, accumulating clinical experience in addition to animal study data makes it an appealing option

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service